Literature DB >> 20123563

Dopamine receptors and L-dopa-induced dyskinesia.

Amandine Berthet1, Erwan Bezard.   

Abstract

In the majority of Parkinson's disease patients, chronic dopamine replacement therapy leads to involuntary aimless movements known as l-dopa-induced dyskinesia. While mechanisms involved in dyskinesia occurrence are still unclear, dopamine receptors undoubtedly have a central role in their pathophysiology. Here we review current knowledge and evidence for their involvement in dyskinesia genesis and manifestation. We propose that an anti-dyskinetic strategy should target the D1/D3 signalling cascade, as targeting D2 receptor signalling seems to inherently convey anti-therapeutic effects deleterious to patients. As more molecular tools are made available, we will better understand the role of each receptor and its associated signalling cascade in Parkinson's disease and L-dopa-induced dyskinesia, hopefully in a way amenable to patients. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20123563     DOI: 10.1016/S1353-8020(09)70827-2

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  19 in total

Review 1.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

2.  Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.

Authors:  Tan Wang; Xuebin Cao; Tian Zhang; Qingqing Shi; Zhibin Chen; Beisha Tang
Journal:  Neurol Sci       Date:  2015-03-19       Impact factor: 3.307

3.  A GIPC1-Palmitate Switch Modulates Dopamine Drd3 Receptor Trafficking and Signaling.

Authors:  Margarita Arango-Lievano; Ozge Sensoy; Amélie Borie; Maithé Corbani; Gilles Guillon; Pierre Sokoloff; Harel Weinstein; Freddy Jeanneteau
Journal:  Mol Cell Biol       Date:  2016-01-19       Impact factor: 4.272

Review 4.  Prospects of statins in Parkinson disease.

Authors:  Avik Roy; Kalipada Pahan
Journal:  Neuroscientist       Date:  2011-01-20       Impact factor: 7.519

5.  An amino acid residue in the second extracellular loop determines the agonist-dependent tolerance property of the human D3 dopamine receptor.

Authors:  Sara Gil-Mast; Sandhya Kortagere; Kokila Kota; Eldo V Kuzhikandathil
Journal:  ACS Chem Neurosci       Date:  2013-03-21       Impact factor: 4.418

6.  PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.

Authors:  Gregory Porras; Amandine Berthet; Benjamin Dehay; Qin Li; Laurent Ladepeche; Elisabeth Normand; Sandra Dovero; Audrey Martinez; Evelyne Doudnikoff; Marie-Laure Martin-Négrier; Qin Chuan; Bertrand Bloch; Daniel Choquet; Eric Boué-Grabot; Laurent Groc; Erwan Bezard
Journal:  J Clin Invest       Date:  2012-10-08       Impact factor: 14.808

7.  The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-03-03       Impact factor: 5.372

8.  The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.

Authors:  Karl Strecker; Michael Adamaszek; Sven Ohm; Florian Wegner; Jürgen Beck; Johannes Schwarz
Journal:  J Neural Transm (Vienna)       Date:  2012-05-10       Impact factor: 3.575

9.  Metabotropic glutamate receptors for Parkinson's disease therapy.

Authors:  Fabrizio Gasparini; Thérèse Di Paolo; Baltazar Gomez-Mancilla
Journal:  Parkinsons Dis       Date:  2013-06-19

10.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Parkinsons Dis       Date:  2011-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.